BR112023022496A2 - Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos - Google Patents

Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos

Info

Publication number
BR112023022496A2
BR112023022496A2 BR112023022496A BR112023022496A BR112023022496A2 BR 112023022496 A2 BR112023022496 A2 BR 112023022496A2 BR 112023022496 A BR112023022496 A BR 112023022496A BR 112023022496 A BR112023022496 A BR 112023022496A BR 112023022496 A2 BR112023022496 A2 BR 112023022496A2
Authority
BR
Brazil
Prior art keywords
preparation
heterocyclic compound
medicines
application
same
Prior art date
Application number
BR112023022496A
Other languages
English (en)
Inventor
Feng He
Guodong Cai
Huaide Dong
Weikang Tao
Xin Li
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of BR112023022496A2 publication Critical patent/BR112023022496A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos. a presente invenção refere-se a um composto heterocíclico contendo nitrogênio, um método de preparação do mesmo, e uma apli-cação do mesmo em medicamentos. especificamente, a presente inven-ção refere-se a um composto heterocíclico contendo nitrogênio repre-sentado pela fórmula geral (im), um método de preparação do mesmo, uma composição farmacêutica compreendendo o composto, e um uso da composição farmacêutica como um agente terapêutico, em particular como um inibidor de parp1, e um uso da composição farmacêutica na preparação de um fármaco para tratamento e/ou prevenção de câncer.
BR112023022496A 2021-05-24 2022-05-24 Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos BR112023022496A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110565410 2021-05-24
CN202110694022 2021-06-22
CN202110856289 2021-07-28
CN202210198679 2022-03-02
PCT/CN2022/094612 WO2022247816A1 (zh) 2021-05-24 2022-05-24 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
BR112023022496A2 true BR112023022496A2 (pt) 2024-01-16

Family

ID=84229501

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022496A BR112023022496A2 (pt) 2021-05-24 2022-05-24 Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos

Country Status (9)

Country Link
EP (1) EP4349836A1 (pt)
JP (1) JP2024519188A (pt)
KR (1) KR20240012437A (pt)
CN (1) CN117177971A (pt)
AU (1) AU2022280845A1 (pt)
BR (1) BR112023022496A2 (pt)
CA (1) CA3219858A1 (pt)
TW (1) TW202313630A (pt)
WO (1) WO2022247816A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202322807A (zh) 2021-10-01 2023-06-16 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
US11939329B2 (en) 2022-01-21 2024-03-26 Xinthera, Inc. PARP1 inhibitors and uses thereof
TW202400596A (zh) 2022-04-28 2024-01-01 美商辛瑟拉股份有限公司 三環parp1抑制劑及其用途
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
AU2008223793B2 (en) 2007-03-08 2012-08-23 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑
CN110840845B (zh) * 2018-11-16 2022-10-21 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
EP3999506A1 (en) 2019-07-19 2022-05-25 Astrazeneca AB Parp1 inhibitors
CA3182980A1 (en) 2020-06-24 2021-12-30 Itf Research Pharma, S.L.U Soft gelatin capsules
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
KR20240012437A (ko) 2024-01-29
AU2022280845A1 (en) 2023-12-14
TW202313630A (zh) 2023-04-01
CN117177971A (zh) 2023-12-05
WO2022247816A1 (zh) 2022-12-01
JP2024519188A (ja) 2024-05-08
CA3219858A1 (en) 2022-12-01
EP4349836A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
BR112023022496A2 (pt) Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
BR112022024120A2 (pt) Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
BR112023001792A2 (pt) Combinações para o tratamento de câncer
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112018076821A2 (pt) derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento contra câncer
BRPI1008000A2 (pt) composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto.
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2022079290A3 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof